Clover Health Investments, Corp. /de (CLOV) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

Company announced Q1 2026 financial results on May 6, 2026, indicating routine quarterly earnings disclosure with no material adverse events mentioned in the filing.
Leadership note: Clay Thornton is identified as Interim Chief Financial Officer, suggesting potential CFO transition or vacancy that investors should monitor for stability concerns.
Company operates as remote-first with no physical headquarters, directing stockholder communications to Delaware agent for service of process, which is an operational structure choice rather than a material business development.

Want the newest filings?

This analysis covers the filing from 2026-05-06. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play

Get it on Google Play Open in app →

Earlier Current Report filings

Filed: 2026-04-01

Clover Health Investments is undergoing a transition in the Chief Financial Officer role, with Peter Kuipers stepping down and Clay Thornton being appointed as the Interim CFO.
Joseph Oldakowski has been appointed as the Company's principal accounting officer, bringing extensive experience in finance and accounting roles at various healthcare organizations.
The departure of the CFO does not appear to be due to any disagreement between the Company and Mr. Kuipers, but rather a planned transition.

Other reports for Clover Health Investments, Corp. /de

Insider Trading Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.